Laboratory Products
Cutting-edge genomic array advances global pharmacogenomic research
Jan 04 2024
Thermo Fisher Scientific responds to the demand for a more inclusive representation of the human genome with the introduction of its latest and most diverse genomic array, the AxiomTM PangenomiX Array*. Built upon the first draft of the pangenome, which incorporated full genetic blueprints from 47 individuals worldwide, this high-throughput microarray offers unparalleled coverage for population-scale disease investigations and pharmacogenomic research.
The prevailing large-scale genomic datasets primarily rely on European and Caucasian cohorts, limiting the understanding of genetic variations in other populations, including African, Asian, and mixed populations. The PangenomiX Array aims to address this gap by providing comprehensive genomic insights across diverse ethnicities, supporting proactive healthcare models emphasising the role of genetics in disease risk and drug response.
Distinguishing itself as the only research solution combining four assays in a single test - SNP genotyping, whole genome copy number variant detection, fixed copy number discovery, blood, and HLA typing - the PangenomiX Array facilitates advancements in disease risk and detection, population-scale research programs, ancestry testing, wellness assessments, drug efficacy trials, and drug development endeavours.
The array incorporates clinically relevant pharmacogenomic markers and pathogenic variants, offering researchers improved whole-genome imputation and a high degree of diversity for testing across various ethnic backgrounds. Already utilised in the analysis of nearly half a million ethnically diverse samples at a prominent US biobank, the PangenomiX Array contributes to inclusive research studies focused on preventing, diagnosing, and treating diseases.
Kim Caple, President of Genetic Sciences at Thermo Fisher Scientific, commented: “The PangenomiX Array marks a significant stride in diversifying genomic datasets, propelling population-scale disease testing to unprecedented levels. This development holds long-term implications for our understanding of human disease, drug development, pharmacogenomics, and ancestry. With its extensive coverage, cost-effectiveness, accuracy, and reproducibility, the array builds on our three decades of dedicated microarray research, aiming to empower research that enhances people's longevity and well-being.”
More information online
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark
Aug 28 2024 Phnom Penh, Cambodia